Breaking new ground in ductal carcinoma in situ management: the promise of intratumoral messenger ribonucleic acid-2752 and pembrolizumab.

ABSTRACT:

SUBMITTER: O'Sullivan CC 

PROVIDER: S-EPMC12272796 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature